Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma - Trial NCT06132438
Access comprehensive clinical trial information for NCT06132438 through Pure Global AI's free database. This Phase 1 trial is sponsored by Charlotte Lemech and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Charlotte Lemech
The University of New South Wales
Timeline & Enrollment
Phase 1
Nov 01, 2023
Sep 01, 2026
Primary Outcome
Percentage of participants with treatment-related adverse events according to NCI CTCAE V5.0.
Summary
In Australia, glioblastoma (GBM) has a higher annual fatality rate than a variety of other
 cancers, such as melanoma, bladder, and kidney tumors. While the 5-year survival rate for
 other cancers, such as breast and prostate cancer, has increased, there have been no notable
 advancements in GBM during the past ten years, and the incidence and mortality patterns have
 barely changed between 1982 and 2011. In particular, GBM poses a challenging therapeutic
 dilemma for patients and physicians due to its aggressive biology and resistance to available
 treatments. Recent studies showed that cytomegalovirus (CMV) is expressed in GBM tumors,
 making it a good target for immunotherapy trials. This phase I trial aims to determine the
 safety and tolerability of the PEP-CMV vaccine in patients with newly diagnosed
 MGMT-unmethylated GBM in combination with one cycle of adjuvant temozolomide.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06132438
Non-Device Trial